How much revenue did Chimerix generate this year?
Chimerix has achieved a revenue of 10.17 M USD this year.
Chimerix Revenue 2024
Chimerix Revenue
10.17 M USD
Ticker
CMRX
ISIN
US16934W1062
WKN
A1T65B
In 2024, Chimerix's sales reached 10.17 M USD, a 3,040.12% difference from the 324,000 USD sales recorded in the previous year.
The Chimerix Revenue history
| YEAR | REVENUE (undefined USD) | GROSS MARGIN (%) |
|---|---|---|
| 2029e | 339 | 0,10 |
| 2028e | 255.19 | 0,13 |
| 2027e | 76.92 | 0,42 |
| 2026e | 35.28 | 0,92 |
| 2025e | 2.57 | 12,60 |
| 2024e | 10.17 | 3,18 |
| 2023 | 0.32 | 100,00 |
| 2022 | 33.82 | 98,70 |
| 2021 | 1.98 | 16,36 |
| 2020 | 5.37 | 6,03 |
| 2019 | 12.52 | 2,59 |
| 2018 | 7.22 | 4,49 |
| 2017 | 4.49 | 7,22 |
| 2016 | 5.7 | 5,68 |
| 2015 | 10.76 | 3,01 |
| 2014 | 4.04 | 8,02 |
| 2013 | 4.37 | 7,41 |
| 2012 | 33.72 | 0,96 |
| 2011 | 12.1 | 2,68 |
| 2010 | 1.72 | 18,84 |
Chimerix Revenue, EBIT, Net Income US16934W1062 · A1T65B
3 years
5 years
10 years
25 Years
Max
Revenue
EBIT
Net Income
Details
Revenue, EBIT and Profit
ⓘUnderstanding Revenue, EBIT, and Income
Gain insights into Chimerix, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Chimerix from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Chimerix’s net earnings, an ultimate measure of its financial health and profitability.
Yearly Analysis and Comparisons
Observe the yearly bars to understand the annual performance and growth of Chimerix. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.
Utilizing Expectations for Investment
The expected values for the forthcoming years offer investors a glimpse into Chimerix’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.
Investment Insights
Leveraging the comparison between Revenue and EBIT helps in assessing Chimerix’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Chimerix’s growth potential.
Chimerix Revenue, EBIT and net profit per share
| Date | Chimerix Revenue | Chimerix EBIT | Chimerix Net Income |
|---|---|---|---|
| 2029e | 339 M undefined | 0 undefined | 55.77 M undefined |
| 2028e | 255.19 M undefined | 75.54 M undefined | 20.57 M undefined |
| 2027e | 76.92 M undefined | -43.8 M undefined | -48.92 M undefined |
| 2026e | 35.28 M undefined | -77 M undefined | -63.04 M undefined |
| 2025e | 2.57 M undefined | -102.46 M undefined | -91.34 M undefined |
| 2024e | 10.17 M undefined | -89.23 M undefined | -80.43 M undefined |
| 2023 | 324,000 undefined | -93.07 M undefined | -82.1 M undefined |
| 2022 | 33.82 M undefined | -60.39 M undefined | 172.17 M undefined |
| 2021 | 1.98 M undefined | -90.51 M undefined | -173.24 M undefined |
| 2020 | 5.37 M undefined | -44.52 M undefined | -43.52 M undefined |
| 2019 | 12.52 M undefined | -45.23 M undefined | -112.58 M undefined |
| 2018 | 7.22 M undefined | -71.6 M undefined | -69.47 M undefined |
| 2017 | 4.49 M undefined | -72.1 M undefined | -70.98 M undefined |
| 2016 | 5.7 M undefined | -77.95 M undefined | -76.39 M undefined |
| 2015 | 10.76 M undefined | -118.25 M undefined | -117.37 M undefined |
| 2014 | 4.04 M undefined | -58.87 M undefined | -59.31 M undefined |
| 2013 | 4.37 M undefined | -28.62 M undefined | -70.55 M undefined |
| 2012 | 33.72 M undefined | -2.78 M undefined | -8.76 M undefined |
| 2011 | 12.1 M undefined | -24.99 M undefined | -35.15 M undefined |
| 2010 | 1.72 M undefined | -25.3 M undefined | -25.46 M undefined |
| Revenue | EBIT | Net Income | |
|---|---|---|---|
| 2010 | 1.72 M USD | -25.3 M USD | -25.46 M USD |
| 2011 | 12.1 M USD | -24.99 M USD | -35.15 M USD |
| 2012 | 33.72 M USD | -2.78 M USD | -8.76 M USD |
| 2013 | 4.37 M USD | -28.62 M USD | -70.55 M USD |
| 2014 | 4.04 M USD | -58.87 M USD | -59.31 M USD |
| 2015 | 10.76 M USD | -118.25 M USD | -117.37 M USD |
| 2016 | 5.7 M USD | -77.95 M USD | -76.39 M USD |
| 2017 | 4.49 M USD | -72.1 M USD | -70.98 M USD |
| 2018 | 7.22 M USD | -71.6 M USD | -69.47 M USD |
| 2019 | 12.52 M USD | -45.23 M USD | -112.58 M USD |
| 2020 | 5.37 M USD | -44.52 M USD | -43.52 M USD |
| 2021 | 1.98 M USD | -90.51 M USD | -173.24 M USD |
| 2022 | 33.82 M USD | -60.39 M USD | 172.17 M USD |
| 2023 | 324,000 USD | -93.07 M USD | -82.1 M USD |
| 2024e | 10.17 M USD | -89.23 M USD | -80.43 M USD |
| 2025e | 2.57 M USD | -102.46 M USD | -91.34 M USD |
| 2026e | 35.28 M USD | -77 M USD | -63.04 M USD |
| 2027e | 76.92 M USD | -43.8 M USD | -48.92 M USD |
| 2028e | 255.19 M USD | 75.54 M USD | 20.57 M USD |
| 2029e | 339 M USD | 0 USD | 55.77 M USD |
Chimerix stock margins US16934W1062 · A1T65B
The Chimerix margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Chimerix. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Chimerix.
3 years
5 years
10 years
25 Years
Max
Gross margin
EBIT margin
Profit margin
Details
Margin
ⓘUnderstanding Gross Margin
The gross margin, expressed as a percentage, delineates the gross profit made from the Chimerix's sales revenue. A higher gross margin percentage indicates that the Chimerix retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.
EBIT Margin Analysis
EBIT margin represents the Chimerix's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.
Revenue Margin Insights
The revenue margin demonstrates the Chimerix's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Chimerix's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.
Interpreting Expectations
The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Chimerix. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.
Comparative Analysis
Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Chimerix's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.
Chimerix Margin History
| Chimerix Gross margin | Chimerix Profit margin | Chimerix EBIT margin | Chimerix Profit margin |
|---|---|---|---|
| 2029e | 100 % | 0 % | 16.45 % |
| 2028e | 100 % | 29.6 % | 8.06 % |
| 2027e | 100 % | -56.94 % | -63.59 % |
| 2026e | 100 % | -218.24 % | -178.69 % |
| 2025e | 100 % | -3,983.83 % | -3,551.38 % |
| 2024e | 100 % | -877.03 % | -790.55 % |
| 2023 | 100 % | -28,723.77 % | -25,337.96 % |
| 2022 | 98.7 % | -178.56 % | 509.08 % |
| 2021 | 100 % | -4,571.21 % | -8,749.5 % |
| 2020 | 100 % | -829.05 % | -810.43 % |
| 2019 | 100 % | -361.26 % | -899.2 % |
| 2018 | 100 % | -991.69 % | -962.19 % |
| 2017 | 100 % | -1,605.79 % | -1,580.85 % |
| 2016 | 100 % | -1,367.54 % | -1,340.18 % |
| 2015 | 100 % | -1,098.98 % | -1,090.8 % |
| 2014 | 100 % | -1,457.18 % | -1,468.07 % |
| 2013 | 100 % | -654.92 % | -1,614.42 % |
| 2012 | 100 % | -8.24 % | -25.98 % |
| 2011 | 100 % | -206.53 % | -290.5 % |
| 2010 | 100 % | -1,470.93 % | -1,480.23 % |
| Gross margin | EBIT margin | Profit margin | |
|---|---|---|---|
| 2010 | 100 % | -1,470.93 % | -1,480.23 % |
| 2011 | 100 % | -206.53 % | -290.5 % |
| 2012 | 100 % | -8.24 % | -25.98 % |
| 2013 | 100 % | -654.92 % | -1,614.42 % |
| 2014 | 100 % | -1,457.18 % | -1,468.07 % |
| 2015 | 100 % | -1,098.98 % | -1,090.8 % |
| 2016 | 100 % | -1,367.54 % | -1,340.18 % |
| 2017 | 100 % | -1,605.79 % | -1,580.85 % |
| 2018 | 100 % | -991.69 % | -962.19 % |
| 2019 | 100 % | -361.26 % | -899.2 % |
| 2020 | 100 % | -829.05 % | -810.43 % |
| 2021 | 100 % | -4,571.21 % | -8,749.5 % |
| 2022 | 98.7 % | -178.56 % | 509.08 % |
| 2023 | 100 % | -28,723.77 % | -25,337.96 % |
| 2024e | 100 % | -877.03 % | -790.55 % |
| 2025e | 100 % | -3,983.83 % | -3,551.38 % |
| 2026e | 100 % | -218.24 % | -178.69 % |
| 2027e | 100 % | -56.94 % | -63.59 % |
| 2028e | 100 % | 29.6 % | 8.06 % |
| 2029e | 100 % | 0 % | 16.45 % |
Chimerix Aktienanalyse
What does Chimerix do?
Chimerix Inc is a biopharmaceutical company focused on the development of antiviral drugs. The company was founded in 2002 and is headquartered in Durham, North Carolina. The history of Chimerix dates back to the research of Dr. George Painter, a renowned scientist in the field of antiviral therapy. He discovered that a certain group of molecules, known as nucleoside analogues, have antiviral properties. The idea was to use these molecules as a starting point for the development of drugs that specifically target viruses. The core idea of Chimerix was to create a new business model that is different from traditional pharmaceutical companies. Instead of focusing on the lengthy and costly development of new compounds, the company wanted to utilize existing molecules and create new drugs through targeted modifications. This approach was not only expected to be faster and cost-effective but also to offer higher chances of success. Chimerix is divided into several business segments. The most important segment is antiviral therapy, where the company focuses on developing drugs against various viruses such as Cytomegalovirus (CMV), Adenovirus, and Herpesvirus. Another business segment of Chimerix is oncology. Here, the company also relies on modifying existing compounds to develop new and effective cancer drugs. One promising molecule currently being developed is Brincidofovir, which not only has antiviral properties but also possesses antitumor properties. In addition to drug development, Chimerix also offers support for clinical trials. The company collaborates with various research institutions and biopharmaceutical companies to test the efficacy and safety of new compounds. The most well-known product of Chimerix is Brincidofovir. This antiviral drug is currently being tested in clinical trials and has the potential to be used against a range of viruses. Its use is particularly promising in patients undergoing immunosuppressive therapy, such as those after a stem cell transplant. Chimerix aims to develop innovative and effective drugs that help patients overcome serious diseases. With its unique business model and close collaboration with the research community, the company has already made promising progress and is an important player in the field of antiviral therapy and oncology. Chimerix ist eines der beliebtesten Unternehmen auf Eulerpool.com.Revenue Details
Understanding Chimerix's Sales Figures
The sales figures of Chimerix originate from the total revenue accrued from goods sold or services provided during a specific time period. These numbers are a direct reflection of the company’s ability to translate its products or services into revenue, indicating the demand and market presence.
Year-to-Year Comparison
Analyzing Chimerix’s yearly sales data offers insights into the company’s growth and stability. An increase in sales suggests a growing demand for its offerings, efficient marketing, or expansion into new markets. Conversely, a decline might indicate market saturation, increased competition, or less effective strategies.
Impact on Investments
Investors often scrutinize Chimerix's sales data to evaluate its financial health and growth prospects. Consistent sales growth can be a promising indicator of the company’s profitability and potential return on investment, influencing stock prices and investor confidence.
Interpreting Sales Fluctuations
Increases in Chimerix’s sales indicate market growth, innovation, or effective marketing, often leading to a surge in stock prices. A decline, however, can signal challenges requiring strategic adjustments to enhance market share and profitability.
Frequently Asked Questions about Chimerix stock
How much was the turnover of the company Chimerix compared to the previous year?
The revenue of Chimerix has increased by 3,040.12% increased compared to the previous year.
What does revenue mean for investors?
The revenue of a company is an important indicator of its financial performance and attractiveness for investors.
Which factors influence the revenue of Chimerix?
The revenue of Chimerix is influenced by various factors, including the demand for its products and services, market conditions, and prices.
How is the revenue of Chimerix measured?
Revenue is typically measured in units referring to the sale of goods and services provided by the company.
How does an increase in sales affect investments?
An increase in revenue can prompt investors to invest more money in the company as it serves as a positive signal for its financial performance and growth prospects.
What are the possible risks associated with a declining revenue?
A decline in revenue can prompt investors to invest less money in the company, as it is a negative signal for its financial performance and growth prospects.
Why is the sales revenue of Chimerix so important for investors?
The revenue of Chimerix is an important indicator of financial performance and attractiveness for investors.
What strategic measures can a company take to increase revenue?
A company can take various strategic measures to increase revenue, including developing new products and services, introducing new pricing models, and expanding into new markets.
How much dividend does Chimerix pay?
Over the past 12 months, Chimerix paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Chimerix is expected to pay a dividend of 0 USD.
What is the dividend yield of Chimerix?
The current dividend yield of Chimerix is .
When does Chimerix pay dividends?
Chimerix pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Chimerix?
Chimerix paid dividends every year for the past 0 years.
What is the dividend of Chimerix?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Chimerix located?
Chimerix is assigned to the 'Health' sector.
Wann musste ich die Aktien von Chimerix kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Chimerix from 9/20/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/20/2024.
When did Chimerix pay the last dividend?
The last dividend was paid out on 9/20/2024.
What was the dividend of Chimerix in the year 2023?
In the year 2023, Chimerix distributed 0 USD as dividends.
In which currency does Chimerix pay out the dividend?
The dividends of Chimerix are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Chimerix
Our stock analysis for Chimerix Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Chimerix Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
